Acitretin

Dermatologic Therapy

Volumn 26, Issue 5, 2013, Pages 390-399

  Ortiz, Noelani E Gonzalez ^a   Nijhawan, Rajiv I ^a   Weinberg, Jeffrey M ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

acitretin; mucocutaneous; psoriasis; retinoid; teratogenicity

Indexed keywords

ALCOHOL; ANTIDIABETIC AGENT; CORTICOSTEROID; ETANERCEPT; ETRETIN; ETRETINATE; GESTAGEN; LIVE VACCINE; METHOTREXATE; MINOCYCLINE; RETINOID; RETINOL; TACROLIMUS; TETRACYCLINE;

ACTINIC KERATOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; BRAIN PSEUDOTUMOR; BURNING SENSATION; CD4 LYMPHOCYTE COUNT; CHEILITIS; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; DEPRESSION; DISEASE SEVERITY; DROWSINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG WITHDRAWAL; DRY SKIN; DYSKERATOSIS; EPIDERMODYSPLASIA VERRUCIFORMIS; EPIDERMOLYTIC HYPERKERATOSIS; ERYTHRODERMIC PSORIASIS; ERYTHROKERATODERMIA VARIABILIS; EYE IRRITATION; HAIR LOSS; HEART INFARCTION; HIP MALFORMATION; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPEROSTOSIS; HYPERVITAMINOSIS; INTRACRANIAL HYPERTENSION; KERATODERMA; LAMELLAR ICHTHYOSIS; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; MONOTHERAPY; NAIL PSORIASIS; NAUSEA; NEURAL TUBE DEFECT; NEVUS; OPTIMAL DRUG DOSE; PANCREATITIS; PATIENT MONITORING; PHYSICAL EXAMINATION; PITYRIASIS RUBRA PILARIS; POROKERATOSIS; PREGNANCY; PREGNANCY TEST; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINITIS; SIDE EFFECT; SKELETON MALFORMATION; SKIN ABRASION; SKIN BIOPSY; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; SYNOSTOSIS; TERATOGENICITY; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; VACCINATION; VERTIGO; VOMITING;

ACITRETIN; MUCOCUTANEOUS; PSORIASIS; RETINOID; TERATOGENICITY;

ACITRETIN; ADULT; DRUG APPROVAL; DRUG RESISTANCE; ETRETINATE; FEMALE; HUMANS; KERATOLYTIC AGENTS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TERATOGENS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84885456831     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12086     Document Type: Article

References (85)

1. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009: 60 (4): 643-659.
2. Soriatane [package insert]. Nutley, NJ: Roche Laboratories, 1997.
3. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012: 148 (1): 95-102.
4. Kragballe K, Jansen CT, Geiger JM, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol 1989: 69 (1): 35-40.
5. Lee E, Koo J,. Single-center retrospective study of long-term use of low-dose acitretin (Soriatane) for psoriasis. J Dermatolog Treat 2004: 15 (1): 8-13.
6. Kurd SK, Gelfand JM,. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009: 60 (2): 218-224.
7. Patton T, Zirwas M, Wolverton S,. Systemic retinoids. In:, Wolverton S, ed. Comprehensive dermatologic drug therapy, 4th ed. Philadelphia, PA: Saunders Elsevier, 2007: 275-300.
8. Geiger JM,. Efficacy of acitretin in severe psoriasis. Skin Therapy Lett 2003: 8 (4): 1-3, 7.
9. Murray HE, Anhalt AW, Lessard R, et al. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J Am Acad Dermatol 1991: 24 (4): 598-602.
10. Goldfarb MT, Ellis CN, Gupta AK, Tincoff T, Hamilton TA, Voorhees JJ,. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol 1988: 18 (4 Pt 1): 655-662.
11. Lassus A, Geiger JM, Nyblom M, Virrankoski T, Kaartamaa M, Ingervo L,. Treatment of severe psoriasis with etretin (RO 10-1670). Br J Dermatol 1987: 117 (3): 333-341.
12. Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ,. Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 1989: 20 (6): 1088-1093.
13. Olsen EA, Weed WW, Meyer CJ, Cobo LM,. A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol 1989: 21 (4 Pt 1): 681-686.
14. Gollnick H, Bauer R, Brindley C, et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol 1988: 19 (3): 458-468.
15. Werner B, Bresch M, Brenner FM, Lima HC,. Comparative study of histopathological and immunohistochemical findings in skin biopsies from patients with psoriasis before and after treatment with acitretin. J Cutan Pathol 2008: 35 (3): 302-310.
16. Patel RV, Weinberg JM,. Psoriasis in the patient with human immunodeficiency virus, part 2: review of treatment. Cutis 2008: 82 (3): 202-210.
17. Buccheri L, Katchen BR, Karter AJ, Cohen SR,. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol 1997: 133 (6): 711-715.
18. Menon K, Van Voorhees AS, Bebo BF, Jr, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010: 62 (2): 291-299.
19. Cassell S, Kavanaugh AF,. Therapies for psoriatic nail disease. A systematic review. J Rheumatol 2006: 33 (7): 1452-1456.
20. Tosti A, Ricotti C, Romanelli P, Cameli N, Piraccini BM,. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009: 145 (3): 269-271.
21. Mukai MM, Poffo IF, Werner B, Brenner FM, Lima Filho JH,. NAPSI utilization as an evaluation method of nail psoriasis in patients using acitretin. An Bras Dermatol 2012: 87 (2): 256-262.
22. Lopez V, Molina I, Marti N, Martin JM, Jorda E,. Severe nail psoriasis with a rapid response to acitretin. Clin Exp Dermatol 2009: 34 (7): e332-e333.
23. Warren RB, Griffiths CE,. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin Dermatol 2008: 26 (5): 438-447.
24. Ozawa A, Ohkido M, Haruki Y, et al. Treatments of generalized pustular psoriasis: a multicenter study in Japan. J Dermatol 1999: 26 (3): 141-149.
25. Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012: 67 (2): 279-288.
26. Lassus A, Geiger JM,. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol 1988: 119 (6): 755-759.
27. Darwich E, Munoz-Santos C, Mascaro JM, Jr,. Erosive pustular dermatosis of the scalp responding to acitretin. Arch Dermatol 2011: 147 (2): 252-253.
28. Katugampola RP, Finlay AY,. Oral retinoid therapy for disorders of keratinization: single-centre retrospective 25 years' experience on 23 patients. Br J Dermatol 2006: 154 (2): 267-276.
29. Zhang XB, Luo Q, Li CX, He YQ, Xu X,. Clinical investigation of acitretin in children with severe inherited keratinization disorders in China. J Dermatolog Treat 2008: 19 (4): 221-228.
30. Ruby LK, Mital MA,. Skeletal deformities following chronic hypervitaminosis A; a case report. J Bone Joint Surg Am 1974: 56 (6): 1283-1287.
31. Gerber A, Raab AP, Sobel AE,. Vitamin A poisoning in adults; with description of a case. Am J Med 1954: 16 (5): 729-745.
32. Glover MT, Peters AM, Atherton DJ,. Surveillance for skeletal toxicity of children treated with etretinate. Br J Dermatol 1987: 116 (5): 609-614.
33. Paige DG, Judge MR, Shaw DG, Atherton DJ, Harper JI,. Bone changes and their significance in children with ichthyosis on long-term etretinate therapy. Br J Dermatol 1992: 127 (4): 387-391.
34. Blanchet-Bardon C, Nazzaro V, Rognin C, Geiger JM, Puissant A,. Acitretin in the treatment of severe disorders of keratinization. Results of an open study. J Am Acad Dermatol 1991: 24 (6 Pt 1): 982-986.
35. Lacour M, Mehta-Nikhar B, Atherton DJ, Harper JI,. An appraisal of acitretin therapy in children with inherited disorders of keratinization. Br J Dermatol 1996: 134 (6): 1023-1029.
36. Graham-Brown RA, Chave TA,. Acitretin for erythrokeratodermia variabilis in a 9-year-old girl. Pediatr Dermatol 2002: 19 (6): 510-512.
37. Nassif PW, Nakandakari S, Fogagnolo L, Contin LA, Alves CJ,. Epidermolytic hyperkeratosis: a follow-up of 23 years of use of systemic retinoids. An Bras Dermatol 2011: 86 (4 Suppl. 1): S72-S75.
38. McNamara IR, Muir J, Galbraith AJ,. Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation. J Heart Lung Transplant 2002: 21 (11): 1201-1205.
39. Shuttleworth D, Marks R, Griffin PJ, Salaman JR,. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 1988: 68 (257): 717-725.
40. Hardin J, Mydlarski PR,. Systemic retinoids: chemoprevention of skin cancer in transplant recipients. Skin Therapy Lett 2010: 15 (7): 1-4.
41. Chen K, Craig JC, Shumack S,. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 2005: 152 (3): 518-523.
42. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995: 13 (8): 1933-1938.
43. George R, Weightman W, Russ GR, Bannister KM, Mathew TH,. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002: 43 (4): 269-273.
44. de Sevaux RG, Smit JV, de Jong EM, van de Kerkhof PC, Hoitsma AJ,. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 2003: 49 (3): 407-412.
45. Harwood CA, Leedham-Green M, Leigh IM, Proby CM,. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol 2005: 141 (4): 456-464.
46. Kadakia KC, Barton DL, Loprinzi CL, et al. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer 2012: 118 (8): 2128-2137.
47. Cheeley J, Sahn RE, Delong LK, Parker SR,. Acitretin for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 2013: 68 (2): 247-254.
48. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998: 92 (10): 3578-3581.
49. Laurberg G, Geiger JM, Hjorth N, et al. Treatment of lichen planus with acitretin. A double-blind, placebo-controlled study in 65 patients. J Am Acad Dermatol 1991: 24 (3): 434-437.
50. Ormerod AD, Campalani E, Goodfield MJ,. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010: 162 (5): 952-963.
51. Jaime TJ, Guaraldi Bde M, Melo DF, Jeunon T, Lerer C,. Disseminated hypertrophic lichen planus: relevant response to acitretin. An Bras Dermatol 2011: 86 (4 Suppl. 1): S96-S99.
52. Kirby B, Watson R,. Pityriasis rubra pilaris treated with acitretin and narrow-band ultraviolet B (Re-TL-01). Br J Dermatol 2000: 142 (2): 376-377.
53. Davis KF, Wu JJ, Murase JE, Rosenberg FR, Sorenson EP, Meshkinpour A,. Clinical improvement of pityriasis rubra pilaris with combination etanercept and acitretin therapy. Arch Dermatol 2007: 143 (12): 1597-1599.
54. Anadolu R, Oskay T, Erdem C, Boyvat A, Terzi E, Gurgey E,. Treatment of epidermodysplasia verruciformis with a combination of acitretin and interferon alfa-2a. J Am Acad Dermatol 2001: 45 (2): 296-299.
55. Iraji F, Faghihi G,. Epidermodysplasia verruciformis: association with isolated IgM deficiency and response to treatment with acitretin. Clin Exp Dermatol 2000: 25 (1): 41-43.
56. Bousema MT, Romppanen U, Geiger JM, et al. Acitretin in the treatment of severe lichen sclerosus et atrophicus of the vulva: a double-blind, placebo-controlled study. J Am Acad Dermatol 1994: 30 (2 Pt 1): 225-231.
57. Skroza N, Proietti I, Bernardini N, et al. Acitretin for treatment of familial porokeratosis palmaris et plantaris disseminate. Eur J Dermatol 2012: 22 (5): 699-700.
58. Borroni RG, Poddighe D, Zecca M, Brazzelli V,. Efficacy of acitretin for porokeratosis in a child with chronic cutaneous graft versus host disease. Pediatr Dermatol 2013: 30 (1): 148-150.
59. Garg T, Ramchander, Varghese B, Barara M, Nangia A,. Generalized linear porokeratosis: a rare entity with excellent response to acitretin. Dermatol Online J 2011: 17 (5): 3.
60. Scott-Lang VE, McKay DA,. Spiny keratoderma successfully treated with acitretin. Clin Exp Dermatol 2013: 38 (1): 91-92.
61. Patel S, Zirwas M, English JC, 3rd,. Acquired palmoplantar keratoderma. Am J Clin Dermatol 2007: 8 (1): 1-11.
62. Al-Mutairi N, Rijhwani M, Nour-Eldin O,. Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy. J Dermatol 2005: 32 (6): 482-486.
63. Booij MT, Van De Kerkhof PC,. Acitretin revisited in the era of biologics. J Dermatolog Treat 2011: 22 (2): 86-89.
64. Young HS, Summers AM, Read IR, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 2006: 126 (2): 453-459.
65. Saurat JH, Geiger JM, Amblard P, et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 1988: 177 (4): 218-224.
66. Lauharanta J, Geiger JM,. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol 1989: 121 (1): 107-112.
67. Ling MR,. Acitretin: optimal dosing strategies. J Am Acad Dermatol 1999: 41 (3 Pt 2): S13-S17.
68. Katz HI, Waalen J, Leach EE,. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 1999: 41 (3 Pt 2): S7-S12.
69. Geiger JM, Saurat JH,. Acitretin and etretinate. How and when they should be used. Dermatol Clin 1993: 11 (1): 117-129.
70. McNamara PJ, Jewell RC, Jensen BK, Brindley CJ,. Food increases the bioavailability of acitretin. J Clin Pharmacol 1988: 28 (11): 1051-1055.
71. Tanew A, Guggenbichler A, Honigsmann H, Geiger JM, Fritsch P,. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991: 25 (4): 682-684.
72. Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R,. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991: 24 (4): 591-594.
73. Iest J, Boer J,. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 1989: 120 (5): 665-670.
74. Lebwohl M,. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999: 4 (3 Pt 2): S22-S24.
75. Ruzicka T, Sommerburg C, Braun-Falco O, et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol 1990: 126 (4): 482-486.
76. Spuls PI, Rozenblit M, Lebwohl M,. Retrospective study of the efficacy of narrowband UVB and acitretin. J Dermatolog Treat 2003: 14 (Suppl. 2): 17-20.
77. Lebwohl M, Menter A, Koo J, Feldman SR,. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 2004: 50 (3): 416-430.
78. Carlin CS, Callis KP, Krueger GG,. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol 2003: 139 (4): 436-442.
79. Gisondi P, Del Giglio M, Cotena C, Girolomoni G,. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008: 158 (6): 1345-1349.
80. Pearce DJ, Klinger S, Ziel KK, Murad EJ, Rowell R, Feldman SR,. Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. Arch Dermatol 2006: 142 (8): 1000-1004.
81. Yeung H, Wan J, Van Voorhees AS, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013: 68 (1): 64-72.
82. Berbis P, Geiger JM, Vaisse C, Rognin C, Privat Y,. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica 1989: 178 (2): 88-92.
83. Gronhoj Larsen F, Steinkjer B, Jakobsen P, Hjorter A, Brockhoff PB, Nielsen-Kudsk F,. Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol 2000: 143 (6): 1164-1169.
84. Van Dooren-Greebe RJ, Lemmens JA, De Boo T, Hangx NM, Kuijpers AL, Van de Kerkhof PC,. Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Br J Dermatol 1996: 134 (1): 71-76.
85. Vahlquist C, Olsson AG, Lindholm A, Vahlquist A,. Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study. Acta Derm Venereol 1995: 75 (5): 377-380.